Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35,857 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for Treatment of Nectin-4-expressing Cancers.
Zhou W, Fang P, Yu D, Ren H, You M, Yin L, Mei F, Zhu H, Wang Z, Xu H, Cao Y, Sun X, Xu X, Bi J, Wang J, Ma L, Wang X, Chen L, Zhang Y, Cen X, Zhu X, Lou L, Liu D, Tan X, Yang J, Meng T, Shen J. Zhou W, et al. Among authors: liu d. Mol Cancer Ther. 2023 Aug 1;22(8):913-925. doi: 10.1158/1535-7163.MCT-22-0743. Mol Cancer Ther. 2023. PMID: 37196158 Free PMC article.
Safety, tolerability, pharmacokinetic characteristics, and immunogenicity of MW33: a Phase 1 clinical study of the SARS-CoV-2 RBD-targeting monoclonal antibody.
Meng X, Wang P, Xiong Y, Wu Y, Lin X, Lu S, Li R, Zhao B, Liu J, Zeng S, Zeng L, Wu Y, Lu Y, Zhang J, Liu D, Wang S, Lu H. Meng X, et al. Among authors: liu j, liu d. Emerg Microbes Infect. 2021 Dec;10(1):1638-1648. doi: 10.1080/22221751.2021.1960900. Emerg Microbes Infect. 2021. PMID: 34346827 Free PMC article. Clinical Trial.
Efficacy, Safety, and Population Pharmacokinetics of MW032 Compared With Denosumab for Solid Tumor-Related Bone Metastases: A Randomized, Double-Blind, Phase 3 Equivalence Trial.
Zhang S, Yin Y, Xiong H, Wang J, Liu H, Lu J, Zhang Q, Zhang L, Zhong J, Nie J, Lei K, Wang H, Yang S, Yao H, Wu H, Yu D, Ji X, Zhang H, Wu F, Xie W, Li W, Yao W, Zhong D, Sun H, Sun T, Guo Z, Wang R, Guo Y, Yu Z, Li D, Jin H, Song H, Chen X, Ma W, Hu Z, Liu D, Guo Y, Tang J, Jiang Z. Zhang S, et al. Among authors: liu h, liu d. JAMA Oncol. 2024 Apr 1;10(4):448-455. doi: 10.1001/jamaoncol.2023.6520. JAMA Oncol. 2024. PMID: 38329745 Free PMC article. Clinical Trial.
CoVac501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity.
Long Y, Sun J, Song TZ, Liu T, Tang F, Zhang X, Ding L, Miao Y, Zhu W, Pan X, An Q, Qin M, Tong X, Peng X, Yu P, Zhu P, Xu J, Zhang X, Zhang Y, Liu D, Chen B, Chen H, Zhang L, Xiao G, Zuo J, Tang W, Zhou J, Li H, Xu Z, Zheng HY, Long XY, Qin Q, Gan Y, Ren J, Huang W, Zheng YT, Jin G, Gong L. Long Y, et al. Among authors: liu t, liu d. Cell Discov. 2022 Feb 1;8(1):9. doi: 10.1038/s41421-021-00370-2. Cell Discov. 2022. PMID: 35102138 Free PMC article.
Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys.
Wang S, Peng Y, Wang R, Jiao S, Wang M, Huang W, Shan C, Jiang W, Li Z, Gu C, Chen B, Hu X, Yao Y, Min J, Zhang H, Chen Y, Gao G, Tang P, Li G, Wang A, Wang L, Zhang J, Chen S, Gui X, Yuan Z, Liu D. Wang S, et al. Among authors: liu d. Nat Commun. 2020 Nov 13;11(1):5752. doi: 10.1038/s41467-020-19568-1. Nat Commun. 2020. PMID: 33188207 Free PMC article.
Antibody-dependent enhancement (ADE) of SARS-CoV-2 pseudoviral infection requires FcγRIIB and virus-antibody complex with bivalent interaction.
Wang S, Wang J, Yu X, Jiang W, Chen S, Wang R, Wang M, Jiao S, Yang Y, Wang W, Chen H, Chen B, Gu C, Liu C, Wang A, Wang M, Li G, Guo C, Liu D, Zhang J, Zhang M, Wang L, Gui X. Wang S, et al. Among authors: liu c, liu d. Commun Biol. 2022 Mar 24;5(1):262. doi: 10.1038/s42003-022-03207-0. Commun Biol. 2022. PMID: 35332252 Free PMC article.
European Society of Intensive Care Medicine clinical practice guideline on fluid therapy in adult critically ill patients. Part 1: the choice of resuscitation fluids.
Arabi YM, Belley-Cote E, Carsetti A, De Backer D, Donadello K, Juffermans NP, Hammond N, Laake JH, Liu D, Maitland K, Messina A, Møller MH, Poole D, Mac Sweeney R, Vincent JL, Zampieri FG, AlShamsi F; European Society of Intensive Care Medicine. Arabi YM, et al. Among authors: liu d. Intensive Care Med. 2024 May 21. doi: 10.1007/s00134-024-07369-9. Online ahead of print. Intensive Care Med. 2024. PMID: 38771364
35,857 results
You have reached the last available page of results. Please see the User Guide for more information.